SNCA and Parkinson disease: In vitro studies have suggested that, in cell lines expressing autosomal dominant alpha synuclein mutations, these therapies reduce levels of the synuclein protein 17, which has led to a phase II clinical trial of the glucosylceramide synthase inhibitor venglustat as a putative neuroprotective in GBA PD (clinicaltrials.gov, NCT02906020).